Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: A model for low-dose chemotherapy radiosensitization

Journal of Thoracic Oncology

Volumn 3, Issue 6, 2008, Pages 563-568

  Zhang, Hong ^a   Hyrien, Ollivier ^a   Pandya, Kishan J ^a   Keng, Peter C ^a   Chen, Yuhchyau ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Box 647 ^*  (United States)

Author keywords

Lung cancer; Paclitaxel; Radiation; Radiosensitization; Statistical modeling

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION; RADIOSENSITIZATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

EID: 44649083128     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181729dbe     Document Type: Article

References (25)

1. Dillman R, Herndon J, Seagren S, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
2. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
3. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-530.
4. Arriagada R, le Chevalier T, Quoix E, et al. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma - a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991;20:1183-1190.
5. Morton RF, Jett JR, McGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 1991;115:681-686.
6. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-2699.
7. Chen Y, Okunieff P. Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am 2004;18:55-80.
8. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324-333.
9. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-328.
10. Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 2004;22:4329-4340.
11. Fletcher GH, Shukovsky LJ. The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 1975;56:383-400.
12. Martel MK, Ten Haken RK, Hazuka MB. Estimation of tumor control probability parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999;24:31-37.
13. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose escalation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49:23-33.
14. Choy H, Safran H, Akerley W, et al. Phase II trial weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998;4:1931-1936.
15. Lau D, Ryu J, Gandara D, et al. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol 1999;9:117-120.
16. Rosenthal DI, Okani O, Corak J, et al. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. Semin Oncol 1997;24:s12096-s12100.
17. Kirkbride P, Gelmon K, Eisenhauer E. Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin Radiat Oncol 1999;9:102-107.
18. Chen Y, Pandya K, Keng P, et al. Schedule dependent pulsed low-dose paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 2001;24:432-437.
19. Chen Y, Pandya K, Keng P, et al. Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 2003;9:969-975.
20. Chen Y, Pandya KJ, Feins R, et al. Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2007.
21. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data, 1st Ed. Boca Raton: Chapman & Hall/CRC, 1998.
22. Werner-Wasik M, Xiao Y, Pequignot E, et al. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001;51:56-61.
23. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43:189-204.
24. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657.
25. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small cell lung cancer. J Clin Oncol 2005;23:8362-8370.